UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001412
Receipt number R000001635
Scientific Title To investigate the efficacy and safety of Yokukansan for patients with insomnia
Date of disclosure of the study information 2008/10/03
Last modified on 2009/09/18 16:10:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

To investigate the efficacy and safety of Yokukansan for patients with insomnia

Acronym

To investigate the efficacy and safety of Yokukansan for patients with insomnia

Scientific Title

To investigate the efficacy and safety of Yokukansan for patients with insomnia

Scientific Title:Acronym

To investigate the efficacy and safety of Yokukansan for patients with insomnia

Region

Japan


Condition

Condition

Psychophysiological insomnia

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of treatment with Yokukansan for patients with psychophysiological insomnia

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Perform PSG before and after administering Yokukansan for seven consecutive days. PSG data will then be investigated with R&K and CAP(Cyclic alternating pattern).

Key secondary outcomes

1. Acti-graph (device to measure activity level) : Device is worn throughout the entire duration of the test, from 3 days prior to performing PSG until the end of test.
2. Sleep diary: Recorded 3 days prior to performing PSG until the end of test.
3. PSQ (Pittsburgh Sleep Quality Index): Recorded before PSG is performed.
4. PVT (psychomotor vigilance task): Performed after PSG testing (1. immediately upon waking, 2. at 9am, 3. at 11am)
5. VAS (visual analog scale): Recorded after PSG is performed (1. immediately upon waking, 2. at 9am, 3. at 11am)
6. SSS (Standford Sleepiness Scale): Raecorded after PSG is performed (1. immediately upon waking, 2. 9:00AM, 3. 11:00AM)
7. SAM (Space Aeromedicine Fatigue Checklist): Recorded after PSG is performed (1. immediately upon waking, 2. 9:00AM, 3. 11:00AM)
8. SMH (St. Mary`s Hospital Sleep Questionnaire): Recorded after PSG is performed (1. 8:00AM)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Divide Yokukansan`s daily dosage of 7.5g into three doses and administer before or between meals for 7 consecutive days.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Patients who have been diagnosed with psychophysiological insomnia according to the diagnostic criteria outlined by Internationl Classification of Sleep Disorder II (ICSD II).
2) Patients who report insomnia of greater than 4 weeks of duration.
3) Age specification: Patients who are between ages 20-65 (at the time of signing informed consent).
4) Patients who have signed consent to participate in this research.
5) There is no gender specification.

Key exclusion criteria

1) Patients with insomnia that accompany schizophrenia and manic-depressive psychosis.
2) Patients with pharmacologically-induced insomnia, including anti-Parkinson`s, anti-hypertensive and steroid-type drugs.
3) Patients with insomnia due to serious psychosomatic disorders.
4) Patients who have sleep-related respiratory disorders, Periodic Limb Movement Disorder and Restless Leg Syndrome.
5) Patients who have taken Kampo medicine within the last 4 weeks.
6) Patients who have taken psychotropic drugs, anti-histamine drugs, or melatonin, etc. within the last 4 weeks.
7) Patients who have participated in research with other interventions.
8) Patients who are otherwise classified as unfit by the attending physicians for the research.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Motohiro Ozone

Organization

The Jikei university school of medicine

Division name

Department of Psychiatry

Zip code


Address

3-25-8,Nishishinbashi,Minatoku,Tokyo

TEL

03-3433-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Motohiro Ozone

Organization

The Jikei university school of medicine

Division name

Department of Psychiatry

Zip code


Address

3-25-8,Nishishinbashi,Minatoku,Tokyo

TEL

03-3433-1111

Homepage URL


Email



Sponsor or person

Institute

The Jikei university school of medicine

Institute

Department

Personal name



Funding Source

Organization

TSUMURA & Co.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 10 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 06 Month 12 Day

Date of IRB


Anticipated trial start date

2008 Year 10 Month 01 Day

Last follow-up date

2009 Year 09 Month 01 Day

Date of closure to data entry

2009 Year 09 Month 01 Day

Date trial data considered complete

2009 Year 09 Month 01 Day

Date analysis concluded

2009 Year 10 Month 01 Day


Other

Other related information



Management information

Registered date

2008 Year 10 Month 02 Day

Last modified on

2009 Year 09 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001635


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name